IMUC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IMUC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. EOM Pharmaceutical Holdings's Total Liabilities for the quarter that ended in Jun. 2018 was $0.40 Mil. EOM Pharmaceutical Holdings's Total Assets for the quarter that ended in Jun. 2018 was $3.83 Mil. Therefore, EOM Pharmaceutical Holdings's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2018 was 0.11.
The historical data trend for EOM Pharmaceutical Holdings's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EOM Pharmaceutical Holdings Annual Data | |||||||||||||||||||||
Trend | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | |||||||||||
Liabilities-to-Assets | Get a 7-Day Free Trial | 0.09 | 0.08 | 0.28 | 0.64 | 0.34 |
EOM Pharmaceutical Holdings Quarterly Data | ||||||||||||||||||||
Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | |
Liabilities-to-Assets | Get a 7-Day Free Trial | 1.61 | 1.08 | 0.34 | 0.29 | 0.11 |
For the Biotechnology subindustry, EOM Pharmaceutical Holdings's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, EOM Pharmaceutical Holdings's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where EOM Pharmaceutical Holdings's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
EOM Pharmaceutical Holdings's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2017 is calculated as:
Liabilities-to-Assets (A: Dec. 2017 ) | = | Total Liabilities | / | Total Assets |
= | 2.361 | / | 7.009 | |
= | 0.34 |
EOM Pharmaceutical Holdings's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2018 is calculated as
Liabilities-to-Assets (Q: Jun. 2018 ) | = | Total Liabilities | / | Total Assets |
= | 0.402 | / | 3.829 | |
= | 0.10 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EOM Pharmaceutical Holdings (OTCPK:IMUC) Liabilities-to-Assets Explanation
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Thank you for viewing the detailed overview of EOM Pharmaceutical Holdings's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Andrew Gengos | director | 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367 |
Gary Titus | director, officer: Chairman and Secretary | SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125 |
Anthony Gregg Lapointe | director | PO BOX 83216, GAITHERSBURG MD 20883-3216 |
Mark A Schlossberg | director | C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544 |
Rahul Singhvi | director | 246 HOLLY DRIVE, CHALFONT PA 18914 |
Helen Susan Kim | director | 3832 BAY CENTER PLACE, HAYWARD CA 94545 |
Richard Chin | director | C/O OXIGENE, INC., 230 THIRD AVENUE, WALTHAM MA 02451 |
Richard Cowell | director | 7840 VIRGINIA OAK DRIVE, GAINSVILLE VA 20155 |
James G. Bender | officer: VP, Product Development & Mfg. | 112 WEST 34TH STREET, 17TH FLOOR, NEW YORK NY 10120 |
Manish Singh | director, officer: President & CEO | 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367 |
Jacqueline Brandwynne | director | 649 STONE CANYON ROAD, LOS ANGELES CA 90077 |
From GuruFocus
By PRNewswire PRNewswire • 10-16-2018
By PRNewswire PRNewswire • 08-15-2018
By PRNewswire • 11-14-2023
By PRNewswire PRNewswire • 07-19-2018
By PRNewswire PRNewswire • 05-15-2018
By PRNewswire PRNewswire • 03-14-2018
By PRNewswire PRNewswire • 10-17-2018
By PRNewswire PRNewswire • 12-02-2021
By PRNewswire • 09-06-2023
By PRNewswire PRNewswire • 08-29-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.